Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Amortization - Intangibles history runs 17 years deep, the most recent figure standing at $172.3 million for Q1 2026.

• In Q1 2026, Amortization - Intangibles rose 11.59% year-over-year to $172.3 million; the TTM figure through Mar 2026 stood at $672.5 million (up 7.43% YoY), while the FY2025 annual figure was $654.7 million, up 4.36% from the prior year.
• Amortization - Intangibles for Q1 2026 stood at $172.3 million, up from $169.7 million in the prior quarter.
• The five-year high for Amortization - Intangibles was $172.3 million in Q1 2026, with the low at $137.4 million in Q4 2022.
• The 5-year median for Amortization - Intangibles is $155.2 million (2024), against an average of $156.6 million.
• The sharpest annual moves came in 2022 and 2023: Amortization - Intangibles jumped 152.37% in 2022, then declined 12.96% in 2023.
• Jazz Pharmaceuticals' Amortization - Intangibles stood at $137.4 million in 2022, then increased by 10.31% to $151.6 million in 2023, then climbed by 4.85% to $158.9 million in 2024, then grew by 6.82% to $169.7 million in 2025, then gained by 1.51% to $172.3 million in 2026.
• Business Quant data shows JAZZ's Amortization - Intangibles at $172.3 million in Q1 2026, $169.7 million in Q4 2025, and $168.4 million in Q3 2025.